STOCK TITAN

GlycoMimetics, Inc. - $GLYC STOCK NEWS

Welcome to our dedicated page for GlycoMimetics news (Ticker: $GLYC), a resource for investors and traders seeking the latest updates and insights on GlycoMimetics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect GlycoMimetics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of GlycoMimetics's position in the market.

Rhea-AI Summary
GlycoMimetics to report Q3 2023 financial results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.08%
Tags
conferences earnings
-
Rhea-AI Summary
GlycoMimetics begins Phase 1a study of GMI-1687 for potential treatment of inflammatory diseases
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.34%
Tags
-
Rhea-AI Summary
GlycoMimetics CEO to present at H.C. Wainwright conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.1%
Tags
conferences
Rhea-AI Summary
GlycoMimetics, Inc. (NASDAQ:GLYC) granted a non-qualified stock option award of 110,000 shares to Gaetano Bonifacio, M.D., the new Vice President, Global Medical Affairs. The option has an exercise price of $1.65 per share and will vest over a period of 36 months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.31%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.64%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.43%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.14%
Tags
none
-
-
Rhea-AI Summary
GlycoMimetics CEO to participate in fireside chat at Jefferies Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.33%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.55%
Tags
GlycoMimetics, Inc.

Nasdaq:GLYC

GLYC Rankings

GLYC Stock Data

19.30M
40.31M
3.08%
53.32%
2.47%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
ROCKVILLE

About GLYC

at glycomimetics, we are committed to helping to make a difference in the lives of people living with sickle cell, cancer, and other serious diseases. our mission is to continue to advance our research and clinical candidates, providing hope for patients as we strive for tomorrow’s breakthrough treatments. glycomimetics is a clinical-stage biotechnology company. we use novel and proprietary glycobiology technology to develop treatments for diseases, particularly where there is high unmet need. since the company’s inception in 2003, we have developed a robust, diversified product pipeline. we are a public company traded on the nasdaq under the symbol glyc.